Instead of fighting the virus itself, this project targets the mosquito's saliva. Think of it like putting a lock on the door that the virus uses to enter your body, regardless of which specific virus the mosquito is carrying. This way, one single shot could protect you from several different diseases like Zika and Dengue at once.
Current vaccines for flaviviruses have severe safety issues and only target specific proteins. This leaves populations vulnerable to multiple different viruses and emerging threats as mosquito vectors spread.
A broad-spectrum vaccine candidate targeting mosquito saliva. The project developed methodologies to isolate these components and validated antibody responses in mice.
If you are a vaccine developer dealing with safety issues in viral protein vaccines — this project developed a mosquito saliva-targeted candidate that protects against multiple flaviviruses. This allows for a single product to cover dengue, yellow fever, Zika, and West Nile diseases.
If you are a health agency dealing with the threat of 250,000 annual deaths from mosquito-borne viruses — this project developed a broad-spectrum vaccine candidate. It improves pandemic preparedness by protecting citizens against both known and unknown mosquito-borne viruses.
If you are a biotech firm dealing with the geographic spread of mosquito vectors in the EU — this project developed a validated proof-of-concept for a pan-flavivirus target. This provides a foundation for clinical evaluation of a disruptive vaccine platform.
Based on available project data, there is no information regarding the unit price or production cost of the vaccine candidate.
The project includes one vaccine developer and is preparing the candidate for clinical evaluation, but specific industrial scaling data is not provided.
Based on available project data, the project is in the development and characterization phase; specific patent or licensing terms are not listed.
The project runs from 2024-01-01 to 2027-12-31, with the goal of making the candidate ready for clinical evaluation by the end of the period.
The project focuses on creating a broad-spectrum candidate to simplify pandemic response, though specific integration protocols are not detailed.
The consortium is heavily weighted toward research, with 7 research institutions and 2 universities. However, it includes 1 industrial vaccine developer and 1 SME, providing a bridge from lab to clinic. The 8-country collaboration (including the US and UK) ensures a broad geographic range of expertise in virology and immunology.
Contact INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT in France
Contact us to explore licensing opportunities for this pan-flavivirus vaccine target.
